The repository administrator has not yet configured an RDF license.
NEW-GENERATION ANTICONVULSANTS IN EPILEPSY: PRACTICAL SELECTION AND SAFETY MONITORING
Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The main goals of treatment are to control seizures, minimize adverse effects, and improve patients' quality of life. In recent years, new-generation antiseizure medicines (ASMs) - brivaracetam, lacosamide, perampanel, cenobamate, cannabidiol, and fenfluramine - have stood out due to diversification of mechanisms and additional clinical options in some pharmacoresistant cases. This article, using an evidence-informed review approach, summarizes indications, efficacy signals, drug-drug interactions, and principles of safety monitoring for these agents. The findings suggest that new-generation ASMs are most often used as add-on therapy; optimal outcomes depend on patient-centered selection tailored to seizure type/syndrome, age and comorbidities, potential drug-drug interactions, and titration rate. In practice, targeted monitoring of treatment retention (persistence), cognitive and psychobehavioral effects, fall risk, and relevant laboratory indicators improves medication safety.
Multidisciplinary Journal of Science and Technology
NEW-GENERATION ANTICONVULSANTS IN EPILEPSY: PRACTICAL SELECTION AND SAFETY MONITORING (PDF)
HTML Summary of #65490 NEW-GENERATION ANTICONVULSANTS IN EPILEPSY: PRACTICAL SELECTION AND SAFETY MONITORING